This page shows the latest Xadago news and features for those working in and with pharma, biotech and healthcare.
Those on Xadago experienced more beneficial “on” time, when their symptoms were reduced, without troublesome uncontrolled involuntary movement (dyskinesia), compared to those receiving a placebo. ... Newron has divided up the commercial rights to
Newron Pharma will not have to conduct any additional clinical trials for its Parkinson's disease drug Xadago in the US, setting up a new FDA filing in the coming weeks. ... The Italian pharma company's partner Zambon is already rolling Xadago (safinamide
neprilysin inhibitor. Novartis. USA. safinamide. Xadago. Parkinson's disease. MAO-B inhibitor. Newron Pharma.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...